Literature DB >> 10090143

Receptor imaging in the diagnosis and treatment of pituitary tumors.

D J Kwekkeboom1, W W de Herder, E P Krenning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10090143     DOI： 10.1007/BF03345484

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  61 in total

1.  In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.

Authors:  W W de Herder; A E Reijs; D J Kwekkeboom; L J Hofland; F R Nobels; H Y Oei; E P Krenning; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1996-12       Impact factor: 3.478

2.  Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors.

Authors:  A Klibanski; M A Shupnik; H A Bikkal; P M Black; B Kliman; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

3.  Quantitative electron microscopic autoradiography of insulin, glucagon, and somatostatin binding sites on islets.

Authors:  Y C Patel; M Amherdt; L Orci
Journal:  Science       Date:  1982-09-17       Impact factor: 47.728

4.  Autoradiographic mapping of somatostatin receptors in the rat central nervous system and pituitary.

Authors:  J C Reubi; R Maurer
Journal:  Neuroscience       Date:  1985-08       Impact factor: 3.590

5.  [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.

Authors:  G Boni; M Ferdeghini; C R Bellina; F Matteucci; E Castro Lopez; G Parenti; R Canapicchi; R Bianchi
Journal:  Q J Nucl Med       Date:  1995-12

6.  Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Authors:  U Plöckinger; M Reichel; U Fett; W Saeger; H J Quabbe
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

7.  In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).

Authors:  G Faglia; N Bazzoni; A Spada; M Arosio; B Ambrosi; F Spinelli; R Sara; C Bonino; F Lunghi
Journal:  J Clin Endocrinol Metab       Date:  1991-10       Impact factor: 5.958

8.  Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.

Authors:  D J Kwekkeboom; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1992-02       Impact factor: 3.478

9.  Bromocriptine therapy for "nonfunctioning" pituitary tumors.

Authors:  D G Johnston; K Hall; A McGregor; W M Ross; P Kendall-Taylor; R Hall
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

10.  Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.

Authors:  M Duet; O Mundler; C Ajzenberg; B Berolatti; P Chedin; L Duranteau; A Warnet
Journal:  Eur J Nucl Med       Date:  1994-07
View more
  6 in total

1.  Receptor imaging in the diagnosis and treatment of pituitary tumors.

Authors:  A Colao; S Lastoria; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 3.  Octreoscan radioreceptor imaging.

Authors:  Aart J van der Lely; Wouter W de Herder; Eric P Krenning; Dik J Kwekkeboom
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 4.  Somatostatin receptor SPECT.

Authors:  Giovanna Pepe; Roy Moncayo; Emilio Bombardieri; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 5.  Somatostatin receptor imaging for neuroendocrine tumors.

Authors:  Wouter W de Herder; Dik J Kwekkeboom; Richard A Feelders; Maarten O van Aken; Steven W J Lamberts; Aart-Jan van der Lely; Eric P Krenning
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

6.  First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.

Authors:  S Baldari; F Ferraù; C Alafaci; A Herberg; F Granata; V Militano; F M Salpietro; F Trimarchi; S Cannavò
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.